IL6 and COVID-19: Anti-IL6 antibodies (Tocilizumab), BTK inhibition with ibrutinib and acalabrutinib, as well as the known JAK inhibitors- Ruxolitinib, Fedratinib, and Baricitinib are part of potential treatment strategies against COVID-19 that combine antiviral and anti-inflammatory agents (135–139).